Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1936 to 1950 of 9127 results

  1. Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 [TSID11921]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Secukinumab biosimilar for treating plaque psoriasis [TSID11992]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Eszopiclone for treating insomnia [TSID12020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Botulinum neurotoxin type E for treating moderate to severe glabellar lines [TSID12155]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. TAK-880 for managing primary immunodeficiency diseases in people hypersensitive to IgA [TSID11883]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Insertion of Stoma Preservation Device

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  9. Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Lutetium (177Lu) oxodotreotide for treating SSTR-positive advanced or inoperable gastroenteropancreatic neuroendocrine tumours in people 12 to 17 years [TSID12154]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) system for pancreatic cystic neoplasms and neuroendocrine tumours

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in children 4 to 11 years [TSID12190]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12399]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Dabrafenib with trametinib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12398]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation